Infliximab in a child with therapy-resistant systemic vasculitis
- 3 November 2005
- journal article
- case report
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 25 (5), 769-771
- https://doi.org/10.1007/s10067-005-0071-7
Abstract
Treatment of systemic vasculitides is usually based on the use of corticosteroids and other immunosuppressive drugs. We describe a 10-year-old girl with systemic vasculitis resistant to immunosuppressive treatment who had a rapid and impressive response to treatment with infliximab.Keywords
This publication has 15 references indexed in Scilit:
- Juvenile polyarteritis: Results of a multicenter survey of 110 childrenThe Journal of Pediatrics, 2004
- Infliximab as a novel therapy for refractory Kawasaki disease.2004
- Prospective Study of TNFα Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic VasculitisJournal of the American Society of Nephrology, 2004
- Treatment with infliximab for a child with Behçet's diseaseArthritis Care & Research, 2003
- Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label studyAnnals Of The Rheumatic Diseases, 2003
- The spectrum of vasculitis in childrenBest Practice & Research Clinical Rheumatology, 2002
- De novo malignancy after paediatric renal replacement therapyArchives of Disease in Childhood, 2001
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- The Mouse/Human Chimeric Monoclonal Antibody cA2 Neutralizes TNF In Vitro and Protects Transgenic Mice from Cachexia and TNF Lethality In VivoCytokine, 1995
- Diagnostic criteria for polyarteritis nodosa in childhoodThe Journal of Pediatrics, 1992